Inventor · disambiguated record
Ning Li
Also filed as: LI NING · LI NING-YI
74 granted patents·75 pending applications·393 citations·filing 1998–2025
99Inventor score
Files withREGENERON PHARMA75SYNLOGIC OPERATING CO INC11UNIV HONG KONG SCIENCE & TECH4UNIV TIANJIN4FUJIAN COSUNTER PHARMACEUTICAL CO LTD3
Top patents by PatentIndex Score
149 records- 0198US12012445B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2023·Granted Jun 18, 2024·4 cites·30 claims
- 0298US11958894B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2023·Granted Apr 16, 2024·5 cites·30 claims
- 0398US11732025B2Anti-VEGF protein compositions and methods for producing the sameREGENERAN PHARMACEUTICALS INC·Filed 2022·Granted Aug 22, 2023·11 cites·30 claims
- 0498US11548932B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2022·Granted Jan 10, 2023·8 cites·30 claims
- 0598US11542317B1Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2022·Granted Jan 3, 2023·11 cites·30 claims
- 0698US11505593B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2022·Granted Nov 22, 2022·13 cites·29 claims
- 0798US11485770B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2022·Granted Nov 1, 2022·6 cites·14 claims
- 0898US11459373B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2021·Granted Oct 4, 2022·8 cites·16 claims
- 0998US11459374B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2022·Granted Oct 4, 2022·13 cites·26 claims
- 1098US11306135B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2021·Granted Apr 19, 2022·7 cites·16 claims
- 1198US11299532B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2021·Granted Apr 12, 2022·8 cites·22 claims
- 1298US11186625B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2020·Granted Nov 30, 2021·10 cites·3 claims
- 1398US11174283B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2021·Granted Nov 16, 2021·13 cites·12 claims
- 1498US11053280B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2020·Granted Jul 6, 2021·19 cites·11 claims
- 1597US12054532B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2021·Granted Aug 6, 2024·2 cites·30 claims
- 1697US12049489B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2023·Granted Jul 30, 2024·2 cites·30 claims
- 1797US12012444B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2023·Granted Jun 18, 2024·2 cites·19 claims
- 1897US11753459B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2022·Granted Sep 12, 2023·5 cites·30 claims
- 1997US11535663B2Methods for producing aflibercept in chemically defined media having reduced aflibercept variantsREGENERON PHARMA·Filed 2021·Granted Dec 27, 2022·6 cites·10 claims
- 2097US11472861B2Methods for producing aflibercept in chemically defined media having reduced aflibercept variantsREGENERON PHARMA·Filed 2021·Granted Oct 18, 2022·5 cites·26 claims
- 2197US11407813B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2021·Granted Aug 9, 2022·3 cites·20 claims
- 2297US11104715B2Methods for producing aflibercept in chemically defined media having reduced aflibercept variantsREGENERON PHARMA·Filed 2020·Granted Aug 31, 2021·5 cites·16 claims
- 2395US10342876B2Process for reducing subvisible particles in a pharmaceutical formulationREGENERON PHARMA·Filed 2015·Granted Jul 9, 2019·17 cites·21 claims
- 2495US9034629B2Recombinant synthesis of medium chain-length alkanesJOULE UNLTD TECHNOLOGIES INC·Filed 2014·Granted May 19, 2015·14 cites·16 claims
- 2594US12338274B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2024·Granted Jun 24, 2025·0 cites·30 claims
- 2694US12319728B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2024·Granted Jun 3, 2025·0 cites·30 claims
- 2794US12202883B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2024·Granted Jan 21, 2025·0 cites·12 claims
- 2894US11505594B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2022·Granted Nov 22, 2022·1 cites·27 claims
- 2994US11180540B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2020·Granted Nov 23, 2021·2 cites·28 claims
- 3094US2025197474A1Anti-vegf protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3193US11471494B2Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cellsSYNLOGIC OPERATING CO INC·Filed 2018·Granted Oct 18, 2022·7 cites·10 claims
- 3293US2024294606A1Anti-vegf protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3392US7507532B2Cancer specific gene MH15MEDIGEN BIOTECHNOLOGY CORP·Filed 2005·Granted Mar 24, 2009·88 cites·5 claims
- 3491US11723932B2Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cellsSYNLOGIC OPERATING CO INC·Filed 2017·Granted Aug 15, 2023·5 cites·7 claims
- 3591US11371971B2High confidence compound identification by liquid chromatography-mass spectrometryREGENERON PHARMA·Filed 2021·Granted Jun 28, 2022·2 cites·20 claims
- 3690US6200546B1Gastrin receptor-avid peptide conjugatesUNIV MISSOURI·Filed 1998·Granted Mar 13, 2001·52 cites·7 claims
- 3788US11959897B2High confidence compound identification by liquid chromatography-mass spectrometryREGENERON PHARMA·Filed 2022·Granted Apr 16, 2024·1 cites·20 claims
- 3888US6921526B2Gastrin receptor-avid peptide conjugatesUNIV MISSOURI·Filed 2002·Granted Jul 26, 2005·16 cites·28 claims
- 3987US12054533B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2022·Granted Aug 6, 2024·0 cites·18 claims
- 4086US2025289868A1Anti-vegf protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 4184US2024415969A1Process for reducing subvisible particles in a pharmaceutical formulationREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4283US12259373B2High confidence compound identification by liquid chromatography-mass spectrometryREGENERON PHARMA·Filed 2024·Granted Mar 25, 2025·0 cites·20 claims
- 4383US12099042B2Use of liquid chromatography and mass spectrometry to characterize oligonucleotidesREGENERON PHARMA·Filed 2021·Granted Sep 24, 2024·1 cites·28 claims
- 4482US7147838B2Gastrin receptor-avid peptide conjugatesUNIV MISSOURI·Filed 2004·Granted Dec 12, 2006·11 cites·21 claims
- 4580US2024280584A1Methods for characterizing low-abundance host cell proteinsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4680US2025281618A1Process for reducing subvisible particles in a pharmaceutical formulationREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 4779US12196761B2Use of LC-MS/MS to quantitate protein biomarkersREGENERON PHARMA·Filed 2023·Granted Jan 14, 2025·0 cites·8 claims
- 4879US2025060346A1Use of liquid chromatography and mass spectrometry to characterize oligonucleotidesREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4978US2025206803A1Methods of characterizing and purifying vegf receptor fusion proteinREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 5077US11592449B2Use of LC-MS/MS to quantitate protein biomarkersREGENERON PHARMA·Filed 2019·Granted Feb 28, 2023·1 cites·18 claims
Showing the top 50 of 149 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Ning Li files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →